Tremfya Shows 94% Crohn's Remission at Three Years in Phase 3 Data
JNJ sits 43% above its 52-week low of $184.66.
Summary
J&J released long-term data from the GALAXI 2 and GALAXI 3 trials showing Tremfya (guselkumab) maintained clinical remission in up to 94% of Crohn's disease patients through three years. The eight-week dosing regimen achieved 94% remission and 52% endoscopic remission, while the four-week regimen showed 91% and 61%, respectively. Additionally, the FUZION study demonstrated consistent perianal fistula remission across key Crohn's subgroups, with 28% of q8w patients achieving the composite endpoint versus 10% on placebo. This data strengthens Tremfya's competitive position in inflammatory bowel disease, a market where J&J faces biosimilar pressure on Stelara. The results could support expanded labeling and increased adoption, though the company has not yet announced regulatory submissions based on these findings.
At the time of this announcement, JNJ was trading at $264.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $635.6B. The 52-week trading range was $184.66 to $281.07. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.